Ophthalmology Search
Ophthalmology Ophthalmology
blepharitis
BLEPHARITIS
Blepharitis is an inflammation process affecting the eyelid margins, eyelash follicles or openings of the anteriorly-placed accessory lacrimal glands and the posteriorly-placed Meibomian glands that causes ocular irritation and redness acutely but usually chronically.
It may have periods of exacerbations and remissions.
It usually occurs in middle-aged adults but can also start in childhood.
Can affect vision by disrupting the surface of the cornea and the bulbar conjunctiva; may influence tear film composition.

Blepharitis References

  1. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  2. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Blepharitis - limited revision. AAO. www.aao.org/ppp. 2011.
  3. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Blepharitis. AAO. http://www.aao.org/preferred-practice-pattern/blepharitis-ppp.
  4. American Optometric Association Original Consensus Panel. Optometric clinical practice guideline. Care of the patient with ocular surface disorders. American Optometric Association. St. Louis, MO; 2011.
  5. Fort G, Mikolich D. Blepharitis. Ferri: Ferri’s clinical advisor. 1st: Mosby, an imprint of Elsevier; 2012.
  6. Ganatra J, Goldstein M. Blepharitis. In: Yanoff M, Duker JS, et al. Ophthalmology. 3rd ed: Mosby, an imprint of Elsevier; 2009.
  7. Shtein RM. Blepharitis. UpToDate. http://uptodate.com. 2015 Mar.
Editor's Recommendations
Most Read Articles
Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extreme sleep duration may up mortality risk in individuals with T2D
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
How to control asthma well: Experts’ perspectives
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Once-weekly insulin as good as once-daily dose?
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.